Below are the most recent publications written about "Thiotepa" by people in Profiles.
-
Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia. 2003 Oct; 17(10):1967-72.
-
Rosales F, Naparstek E, Varadi G, Or R, Slavin S, Nagler A. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. Leuk Res. 1999 Oct; 23(10):947-52.
-
Moore HC, Mick R, Solin LJ, Sickles C, Mangan PA, Luger SM, Fox KR, Schuchter LM, Loh E, Porter DL, Schuster S, Buzby GP, Glatstein E, Silberstein LE, Stadtmauer EA. Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol. 1999 Aug; 10(8):929-36.
-
Rosales F, Peylan-Ramu N, Cividalli G, Varadi G, Or R, Naparstek E, Slavin S, Nagler A. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplant. 1999 May; 23(9):861-5.
-
Nagler A, Finlander R, Or R, Naparstek E, Varadi G, Slavin S. The role of thiotepa in autologous bone marrow transplantation for acute leukemia. Leuk Res. 1998 Nov; 22(11):991-5.
-
Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O'Reilly RJ, Young JW. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998 Feb 01; 91(3):1083-90.
-
Shapiro CL, Dezube BJ, Tretyakov O, Wright J, Cap B, Henderson IC, Hayes DF. Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. Clin Cancer Res. 1995 Aug; 1(8):791-6.
-
Stadtmauer EA, Hodi FS, Sickles C, Biggs DD, Mangan P, Buzby G, Zaleta E, Silberstein L. High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer. Prog Clin Biol Res. 1994; 389:487-95.
-
O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992 Aug; 10(8):1352-8.
-
Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis RL, O'Dwyer PJ. Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma. Gynecol Oncol. 1991 Dec; 43(3):242-6.